Compare VPG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VPG | ADCT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.5M | 484.4M |
| IPO Year | 2010 | 2019 |
| Metric | VPG | ADCT |
|---|---|---|
| Price | $44.78 | $3.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $53.50 | $7.75 |
| AVG Volume (30 Days) | 209.6K | ★ 759.1K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $307,202,000.00 | $81,357,000.00 |
| Revenue This Year | $7.21 | N/A |
| Revenue Next Year | $6.92 | $66.49 |
| P/E Ratio | $111.93 | ★ N/A |
| Revenue Growth | 0.22 | ★ 14.85 |
| 52 Week Low | $18.57 | $1.05 |
| 52 Week High | $56.25 | $4.98 |
| Indicator | VPG | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 52.95 | 43.30 |
| Support Level | $44.01 | $3.65 |
| Resistance Level | $48.61 | $3.87 |
| Average True Range (ATR) | 2.64 | 0.21 |
| MACD | 0.36 | -0.04 |
| Stochastic Oscillator | 67.19 | 29.73 |
Vishay Precision Group Inc manufactures and markets sensors and sensor-based measurement systems, as well as specialty resistors and strain gages based on proprietary technology. The company provides precision products and solutions, many of which are designed-in by customers, specializing in the growing markets of stress, force, weight, pressure, and current measurements. The company reports in three product segments: Sensors segment, Weighing Solutions segment, and Measurement Systems segment. It has a business presence in the United States and other countries. It generates the maximum of its revenue from the United States.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).